Cellid

Seoul, South Korea Founded: 2014 • Age: 12 yrs Listed
Personalized vaccines for cancer and infectious diseases are developed.

About Cellid

Cellid is a publicly listed company based in Seoul (South Korea) founded in 2014. Personalized vaccines for cancer and infectious diseases are developed. The company has 56 employees. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer.

Company details

Cellid was founded in 2014 and is headquartered in Seoul, South Korea. Operations focus on the biotechnology sector, where a platform called CeliVax is utilized to activate the immune system against cancer cells. Personalized vaccines are being developed for cancer and infectious diseases. Pipeline candidates include BVAC-C, investigated for cervical, head, and neck cancers, and BVAC-B for gastric cancer, both in phase II clinical trials.

  • Headquarters Seoul, South Korea
  • Employees 56
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website cellid.co.kr
  • Legal Name Cellid Co., Ltd.
Key Metrics
  • Annual Revenue
    $6.12 M (USD)
    112.28
    as on Dec 31, 2025
  • Net Profit
    -$8.36 M (USD)
    1.55
    as on Dec 31, 2025
  • EBITDA
    -$6.36 M (USD)
    3.64
    as on Dec 31, 2025
  • Investors
  • Employee Count
    56

Funding Insights of Cellid

  • Total Rounds 4
  • Investors Count 5

All 4 funding rounds of Cellid with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2016Series A––
Jun 2015Series A–DSC Investment, DAOL Investment
–
Jun 2014Series A––
Jun 2014Series A––
Valuation history

5 investors in total: 5 institutional.

Investors in Cellid

Cellid has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include DSC Investment, Green crosscell and Amicogen.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity and innovation services are provided by STIC Investments.
stic.co.krSeoul, South Korea
Early-stage venture capital is invested primarily in South Korean startups.
2012dscinvestment.comSeoul, South Korea
Venture capital fund
daolinvestment.comSeongnam-si, South Korea
Enzymes and biotech solutions for pharma and industry are developed.
2000amicogen.comSouth Korea
Immunotherapy products and cryopreservation of cord blood
1992greencrosscell.comSeoul, South Korea
Premium access

Investor details for Cellid

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

IPO & Listings of Cellid

Cellid is a publicly listed company on the KRX with ticker symbol 299660 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Feb 2019
  • Listed onKRX: 299660
  • Listed entityCellid Co., Ltd.
  • Exchange sectorHealth technology
  • ISINKR7299660001
  • Share price2,310.00 KRW (+0.87% on the day) · 2026-10-14
  • Market capitalisation67,561,818,180.00 KRW
  • EPS (diluted, trailing year)-928.20 KRW
  • Volume (last session)256,282

Financials of Cellid

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
20258.84B KRW-12.07B KRW-9.19B KRW
20244.17B KRW-12.26B KRW-9.54B KRW
2023-11.61B KRW-12.31B KRW
2022480.0M KRW-22.86B KRW-12.31B KRW
2021909.1M KRW-13.07B KRW-19.40B KRW
Premium access

Detailed financial statements for Cellid

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Cellid

4 dated milestones of Cellid across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cellid is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series A,.
  4. IPO Lists on the stock exchange (IPO).

Web traffic of Cellid

The website of Cellid (cellid.co.kr) receives about 3.9K visits a month and ranks #3,891,169 among all websites worldwide, #4,942 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.9K

    ▼ 9.1% vs previous month

  • Unique visitors
    1.7K

    per month

  • Global rank
    #3,891,169

    among all websites

  • Category rank
    #4,942

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Cellid. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
yakup.com
yakup.com
100%
#118,603–
pharmnews.com
100%
#274,610View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cellid

Premium access

Complete news archive for Cellid

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cellid

Cellid was founded in 2014.

Cellid is headquartered in Seoul, South Korea.

Cellid has 56 employees.

Annual revenue of Cellid is $6.12M as on Dec 31, 2025.

Cellid was founded in 2014 and is headquartered in Seoul, South Korea. Operations focus on the biotechnology sector, where a platform called CeliVax is utilized to activate the immune system against cancer cells. Personalized vaccines are being developed for cancer and infectious diseases. Pipeline candidates include BVAC-C, investigated for cervical, head, and neck cancers, and BVAC-B for gastric cancer, both in phase II clinical trials.

Yes, Cellid is publicly traded on KRX under the ticker symbol 299660.

Cellid has 5 investors. Key investors include DSC Investment, Green crosscell, Amicogen, STIC Investments, and DAOL Investment.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available